FluidAI is a healthcare technology platform that combines an inline surgical-drain sensing device (Origin) with software/AI modules (Stream ecosystem) to detect biochemical changes in surgical effluent and support earlier identification of post-operative complications.
Published May 15, 2026
Unlike mainstream SaaS, hospital-deployed medical devices often have limited public reviews due to regulatory context, procurement norms, and confidentiality.
No credible, product-specific G2/Capterra profile for FluidAI Medical was found during research.
A key complication: searches for "FluidAI reviews" surfaced similarly named, unrelated products on review platforms, so their quotes are excluded from evidence-based evaluation of FluidAI.
Direct end-user community threads (Reddit / Hacker News) specifically discussing FluidAI Medical were not readily discoverable in high-signal forums during this pass.
FluidAI lists multiple study initiatives and pilots, including feasibility work on effluent biomarkers, economic evaluations, and pilots exploring at-home monitoring.
Critical evaluation:
Multiple outlets and the company report FDA 510(k) clearance for Origin.
Critical evaluation:
Get a comprehensive analysis of FluidAI including market position, competitive landscape, adoption trends, and peer benchmarks.
Download full report →Most public statements are:
Example (vendor blog, not a consumer review):
Critical note: this is closer to a study endorsement or a clinician comment within a vendor-hosted post than a verified customer review, and it is presented on the vendor’s site.
A vendor-published post describes a phased study context for detecting leaks and preventing infection. The post outlines sequential study phases and provides context on clinical intent and expected impact.
Critical evaluation:
FluidAI is a healthcare technology company focused on data-driven post-operative surgical recovery, combining:
The product detects biochemical changes in surgical effluent (for example, pH; some descriptions also reference electrical conductivity and temperature) that may indicate complications such as anastomotic leaks, with the goal of supporting earlier clinical intervention compared with symptom-based detection.
Recent regulatory and commercial developments include U.S. FDA 510(k) clearance for Origin, which may facilitate expansion into the U.S. hospital market.